8-K: Outlook Therapeutics Receives FDA Complete Response Letter for ONS-5010

Outlook Therapeutics announced the FDA issued a Complete Response Letter for its ONS-5010 BLA resubmission for wet AMD, citing a lack of substantial evidence of effectiveness.

Summary

• The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Outlook Therapeutics' biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD).
• The CRL indicated that the FDA cannot approve the application in its present form due to a single deficiency: a lack of substantial evidence of effectiveness.
• The FDA advised that ONS-5010 did not meet the primary efficacy endpoint in the NORSE EIGHT trial and recommended that confirmatory evidence of efficacy be submitted to support the application.
• The FDA reiterated that the NORSE TWO trial met its primary endpoint for effectiveness.
• No other outstanding deficiencies were identified in the BLA by the FDA.
• Outlook Therapeutics plans to meet with the FDA to seek additional clarity on requirements for potential US approval.
• LYTENAVA (bevacizumab gamma), the European equivalent of ONS-5010, was granted Marketing Authorization by the European Commission in the EU and by the MHRA in the UK for wet AMD.
• LYTENAVA became commercially available in Germany and the UK in June 2025, marking it as the first and only authorized ophthalmic formulation of bevacizumab for wet AMD in these regions.

Sentiment

Score: 3

Explanation: The FDA's Complete Response Letter for ONS-5010's BLA resubmission is a significant setback for US market entry, requiring additional efficacy data. While European approval and commercialization are underway, the US market remains a major hurdle, negatively impacting the company's near-term prospects.

Positives

• The FDA's Complete Response Letter identified no other outstanding deficiencies in the BLA beyond the efficacy concern.
• The NORSE TWO trial met its primary endpoint for effectiveness, which was acknowledged by the FDA.
• LYTENAVA (bevacizumab gamma) has already received Marketing Authorization from the European Commission and the MHRA in the UK for wet AMD.
• Commercial launch of LYTENAVA commenced in Germany and the UK in June 2025, establishing a market presence in Europe.

Negatives

• The FDA issued a Complete Response Letter for the ONS-5010 BLA resubmission, preventing immediate approval in the U.S.
• The primary reason for the CRL was a lack of substantial evidence of effectiveness, specifically because ONS-5010 did not meet the primary efficacy endpoint in the NORSE EIGHT trial.
• The FDA recommended submitting confirmatory evidence of efficacy, which implies further clinical trials or data collection will be required for US approval.

Risks

• Inability to successfully address the issues identified in the FDA's Complete Response Letter, potentially leading to further delays or failure to obtain US approval for ONS-5010.
• Uncertainty regarding the content and timing of future decisions by regulatory bodies, including the FDA.
• The sufficiency of Outlook Therapeutics' financial resources to conduct additional clinical trials or generate the required confirmatory evidence of efficacy.
• General risks associated with developing and commercializing pharmaceutical product candidates.
• Uncertainty of market conditions and future impacts related to macroeconomic factors, including ongoing overseas conflicts, tariffs, trade tensions, fluctuations in interest rates, inflation, and potential future bank failures.

Future Outlook

Outlook Therapeutics plans to meet with the FDA to receive additional clarity on their requirements to potentially approve ONS-5010 in the U.S. The company also intends to continue its efforts to expand the commercial availability of LYTENAVA in additional markets in Europe.

Management Comments

• "While we are very disappointed with this outcome, we intend to meet with the FDA to receive additional clarity on their requirements to potentially approve the first on-label bevacizumab product specifically formulated, manufactured, and packaged for intravitreal use in the United States. We remain committed to providing patients with a safe and effective alternative to compounded Avastin manufactured in the United States." Bob Jahr, Chief Executive Officer of Outlook Therapeutics.

Industry Context

The filing highlights the significant regulatory hurdles for new ophthalmic treatments in the U.S., particularly for conditions like wet AMD where off-label compounded bevacizumab (Avastin) is widely used. Outlook Therapeutics aims to provide an on-label, specifically formulated alternative, but faces a more stringent regulatory environment in the U.S. compared to its successful marketing authorizations in the EU and UK. This situation underscores the challenge of differentiating and gaining approval for a product that competes with an established, albeit off-label, standard of care.

Comparison to Industry Standards

• The FDA's requirement for 'confirmatory evidence of efficacy' after a pivotal trial (NORSE EIGHT) failed its primary endpoint is a standard regulatory response, indicating that the existing data is insufficient for approval by U.S. standards.
• The successful primary endpoint achievement in NORSE TWO, while positive, was not enough to offset the NORSE EIGHT outcome for U.S. approval, demonstrating the FDA's emphasis on consistent and robust efficacy across multiple pivotal trials.
• The Marketing Authorizations granted by the European Commission and MHRA for LYTENAVA indicate a different regulatory threshold or interpretation of the clinical data in Europe compared to the U.S. FDA.
• The wet AMD market is highly competitive, dominated by anti-VEGF therapies like Regeneron's Eylea, Novartis's Lucentis, and Roche's Vabysmo. Outlook Therapeutics' ONS-5010 aimed to be the first on-label bevacizumab, a drug widely used off-label as compounded Avastin, positioning it against both branded and compounded alternatives.

Stakeholder Impact

• Shareholders are highly likely to experience a negative impact on the company's stock value due to the significant delay and increased uncertainty regarding U.S. market approval for ONS-5010.
• Patients in the U.S. will continue to rely on existing treatments, including off-label compounded bevacizumab, as the on-label ONS-5010 will not be immediately available.
• Employees may face uncertainty regarding the company's U.S. development pipeline and future strategic direction, potentially impacting morale and resource allocation.

Next Steps

• Outlook Therapeutics management will host a corporate update conference call and webcast on August 28, 2025, at 8:30 AM ET.
• The company intends to meet with the FDA to receive additional clarity on their requirements for potential US approval.
• Outlook Therapeutics plans to continue its efforts to expand into additional markets in Europe for LYTENAVA.

Key Dates

Recommendation

The FDA's Complete Response Letter, specifically citing a lack of substantial evidence of effectiveness from the NORSE EIGHT trial, represents a major setback for Outlook Therapeutics' primary product candidate, ONS-5010, in the critical U.S. market. While the company plans to engage with the FDA, the requirement for 'confirmatory evidence of efficacy' suggests a need for additional, potentially lengthy and costly clinical trials. This significantly delays any potential revenue generation from the U.S. and introduces substantial uncertainty regarding the product's future in this market. Despite European approvals, the U.S. market is crucial for the company's valuation. This news is highly negative and warrants a strong sell recommendation due to increased risk and prolonged time to market in the largest pharmaceutical market.

Keywords

Outlook Therapeutics, ONS-5010, LYTENAVA, FDA, Complete Response Letter, CRL, wet AMD, bevacizumab, ophthalmic, biologics license application, BLA, regulatory update, biopharmaceutical, NORSE EIGHT, NORSE TWO